Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (141-150 of 247) with videos related to

Pageof 25
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 29, 2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumoursJeffrey R Infante, Glen J Weiss, Suzanne Jones, et al.
Cancer|April 13, 2018
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signaturesDavid R Spigel, Howard A Burris, F Anthony Greco, et al.
JCO Precision Oncology|January 7, 2022
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology ClinicsEmma G Sturgill, Amanda Misch, Rebecca Lachs, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancerDavid R Spigel, John D Hainsworth, Jitendra G Gandhi, et al.
Investigational New Drugs|November 9, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinibGrace K Dy, Jeffrey R Infante, S Gail Eckhardt, et al.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2018
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)John D Hainsworth, David M Waterhouse, Kent C Shih, et al.
Cancer|September 7, 2002
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trialF Anthony Greco, James R Gray, Dana S Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast CancerLee S Schwartzberg, Denise A Yardley, Anthony D Elias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerIan E Krop, Muralidhar Beeram, Shanu Modi, et al.
Clinical Breast Cancer|November 26, 2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)Denise A Yardley, Robyn R Young, Kerin B Adelson, et al.
Pageof 25

Showing results (141-150 of 247) with videos related to

Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|September 29, 2014
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumoursJeffrey R Infante, Glen J Weiss, Suzanne Jones, et al.
Cancer|April 13, 2018
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signaturesDavid R Spigel, Howard A Burris, F Anthony Greco, et al.
JCO Precision Oncology|January 7, 2022
Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology ClinicsEmma G Sturgill, Amanda Misch, Rebecca Lachs, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancerDavid R Spigel, John D Hainsworth, Jitendra G Gandhi, et al.
Investigational New Drugs|November 9, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinibGrace K Dy, Jeffrey R Infante, S Gail Eckhardt, et al.
Lung Cancer (Amsterdam, Netherlands)|March 25, 2018
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)John D Hainsworth, David M Waterhouse, Kent C Shih, et al.
Cancer|September 7, 2002
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trialF Anthony Greco, James R Gray, Dana S Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2017
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast CancerLee S Schwartzberg, Denise A Yardley, Anthony D Elias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerIan E Krop, Muralidhar Beeram, Shanu Modi, et al.
Clinical Breast Cancer|November 26, 2021
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)Denise A Yardley, Robyn R Young, Kerin B Adelson, et al.
Pageof 25